Hanmi Pharmaceutical, a biopharma company in Korea that focuses on oncology, obesity/metabolism, and rare diseases, has entered into a Clinical Trial Collaboration and Supply Agreement with MSD (Merck & Co., Inc.)   Under the agreement, Hanmi Pharmaceutical will conduct a phase 1 clinical trial to evaluate the safety and efficacy of its immuno-oncology drug, BH3120, in combination with MSD’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with progressive or metastatic solid...